ПАТЕНТНЫЙ ПОИСК В РФ
НОВЫЕ ПАТЕНТЫ, ЗАЯВКИ НА ПАТЕНТ
БИБЛИОТЕКА ПАТЕНТОВ НА ИЗОБРЕТЕНИЯ

Therapeutic compositions and methods useful in modulating protein tyrosine phosphatases (патент US № 7993639)

Официальная публикация
патента US № 7993639

PDF откроется в новом окне.
Патентный поиск по классам МПК-8:

Класс A61K45/00 Лекарственные препараты, содержащие активные ингредиенты, не отнесенные к группам  31/00

Класс A01N55/02 .содержащие атомы металла

Класс A01N59/16 .тяжелые металлы; их соединения

Класс A61K31/29  ..сурьму или висмут

Класс A61K31/496  ....не конденсированные пиперазины, содержащие дополнительно гетероциклические кольца, например рифампин, тиотиксен

Класс A61K31/555  ..содержащие тяжелые металлы, например гемин, гематин, меларсопрол

Класс A61K38/19 ...цитокины; лимфокины; интерфероны

Класс A61K38/21 ....интерфероны


Классы МПК:A61K45/00 Лекарственные препараты, содержащие активные ингредиенты, не отнесенные к группам  31/00
A01N55/02 .содержащие атомы металла
A01N59/16 .тяжелые металлы; их соединения
A61K31/29 ..сурьму или висмут
A61K31/496 ....не конденсированные пиперазины, содержащие дополнительно гетероциклические кольца, например рифампин, тиотиксен
A61K31/555 ..содержащие тяжелые металлы, например гемин, гематин, меларсопрол
A61K38/19 ...цитокины; лимфокины; интерфероны
A61K38/21 ....интерфероны
Автор(ы):Yi, Taolin (Solon, OH, US)
Патентообладатель(и):The Cleveland Clinic Foundation (Cleveland, OH, US)
Приоритеты:
подача заявки
25.02.2008
публикация патента
09.08.2011

РЕФЕРАТ (Abstract)

In one embodiment, a therapeutic composition containing a pentavalent antimonial is provided. The pentavalent antimonial can be sodium stibogluconate, levamisole, ketoconazole, and pentamidine and biological equivalents of said compounds. Additionally, pentavalent antimonials that can be used in accordance with the present invention may be any such compounds which are anti-leishmaniasis agents. The therapeutic composition of this embodiment contains an effective amount of pentavalent antimonial that can be used in treating infectious diseases. The types of diseases that can be treated with the present invention include, but are not limited to, the following: diseases associated with PTPase activity, immune deficiency, cancer, infections (such as viral infections), hepatitis B, and hepatitis C. The types of cancers that the present embodiment can be used to treat include those such as lymphoma, multiple myeloma, leukemia, melanoma, prostate cancer, breast cancer, renal cancer, bladder cancer. The therapeutic composition enhances cytokine activity. The therapeutic composition may include a cytokine, such as interferon α, interferon β, interferon γ, or granulocyte/macrophage colony stimulating factor.

ФОРМУЛА ИЗОБРЕТЕНИЯ (CLAIMS)

I claim:

1. A method of treating cancer in a patient in need thereof comprising administering to said patient a therapeutically effective amount of a sodium stibogluconate and interferon alpha, wherein said cancer is selected from the group consisting of lymphoma, multiple myeloma, leukemia, melanoma, prostate cancer, breast cancer, renal cancer, bladder cancer, and combinations thereof.

2. The method of claim 1, wherein said administration is parenteral.

3. The method of claim 2, wherein said parenteral administration is intravenous.

4. The method of claim 1, wherein said administration is of a sodium stibogluconate and interferon alpha is simultaneous.

5. The method of claim 1, wherein sodium stibogluconate first is administered followed by the subsequent administration of interferon alpha.

6. The method of claim 1, wherein interferon alpha is administered first followed by the subsequent administration of sodium stibogluconate.

7. The method of claim 5, wherein said subsequent administration is the same day.

8. The method of claim 5, wherein said subsequent administration is the following day.

9. The method of claim 5, wherein said subsequent administration is within one week.

10. The method of claim 6, wherein said subsequent administration is the same day.

11. The method of claim 6, wherein said subsequent administration is the following day.

12. The method of claim 6, wherein said subsequent administration is within one week.

13. The method of claim 1, wherein said effective amount of a sodium stibogluconate is from about 10 ug/mL, to about 400 mg/mL.

14. The method of claim 1, wherein said effective amount of a sodium stibogluconate is from about 25 ug/mL, to about 100 mg/mL.

15. The method of claim 1, wherein said effective amount of a sodium stibogluconate is from about 10 ug/mL, to about 20 mg/mL.

16. The method of claim 1, wherein said effective amount of a sodium stibogluconate is about 25 mg/mL.

17. The method of claim 1, wherein said effective amount of inteferon-alpha is about 2×108 IU/mg.

18. The method of claim 1, wherein said effective amount of inteferon-alpha is about 500,000 IU.


Предыдущий   патент US   Следующий

Наверх